Skip to contentM
Marker Therapeutics, Inc.
M
MRKRMarker Therapeutics, Inc. Source filing unavailable
Q3 2015 · —
Revenue—
Net Income$28.50M$28.50MN/M vs Q3 2014N/M vs Q2 2015 No earnings release is on file for this quarter. Its figures came with the 10-Q.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
EPS Diluted
$4.23$4.23N/M vs Q3 2014N/M vs Q2 2015 Operating Income-$1,737,978— Operating Cash Flowderived-$1,664,794N/M Filing lag